ARTICLE | Deals
Century deal hands BMS another chance to be an early mover, with iPS immune cells, γδ T cells
BMS’s Vessey aims to improve on existing cell therapies, break new ground with $150M deal
January 13, 2022 12:02 AM UTC
Updated on Jan 13, 2022 at 11:34 PM UTC
BMS is teaming up with Philadelphia-based Century in a deal that brings the pioneering immuno-oncology pharma into a new technology space — iPS-derived immune cell therapies — and sets it up to be among the first movers in γδ T cell therapies.
On Monday, the companies announced a partnership to develop and commercialize up to four induced pluripotent stem (iPS) cell-derived engineered NK and T cell therapies based on Century’s platform. ...